MedTrace Logo

A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

NCT05205629 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-03-23

No results posted yet for this study

Summary

This study is a prospective, single-center, observational real-world study. It is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with Donafenib combined with TACE-based treatment, so as to observe and evaluate the efficacy and safety of Donafenib combined with TACE-based treatment in patients with unresectable HCC.

Conditions

Interventions

DRUG

Donafenib combined with TACE

Donafenib(200mg bid po) combined with TACE

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-30
Primary Completion
2024-01-30
Completion
2024-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05205629 on ClinicalTrials.gov